| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Net revenue | ||||||
23,604 | 13,017 | |||||
Cost of revenue | ||||||
9,741 | 7,283 | |||||
Gross profit | ||||||
13,863 | 5,734 | |||||
Operating expenses: | ||||||
Research, development and clinical trials | ||||||
19,870 | 13,656 | |||||
Selling, general and administrative | ||||||
23,596 | 12,315 | |||||
Total operating expenses | ||||||
43,466 | 25,971 | |||||
Loss from operations | ||||||
-29,603 | -20,237 | |||||
Other income (expense): | ||||||
Interest expense | ||||||
4,353 | 2,720 | |||||
Change in fair value of preferred stock warrant liability | ||||||
341 | 545 | |||||
Other income (expense), net | ||||||
790 | -213 | |||||
Total other expense, net | ||||||
-3,904 | -3,478 | |||||
Loss before income taxes | ||||||
-33,507 | -23,715 | |||||
Provision for income taxes | ||||||
40 | 41 | |||||
Net loss | ||||||
-33,547 | -23,756 | |||||
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-2.36 | -17.48 | |||||
Weighted average common shares outstanding, basic and diluted | ||||||
14,204 | 1,358 | |||||